The efficacy of photodynamic therapy for the treatment of a large number of skin diseases, in particular non-malignant skin cancer, has been reported by a number of studies. It has been demonstrated to be particularly beneficial for large or multiple lesions, especially where good cosmesis is required. However for PDT to become established in routine clinical practice further comparative multi-center studies with currently accepted standard techniques are required.
Introduction

Light in Therapy
The use of light in the treatment of skin conditions, with or without photosensitizers, has a long history. Early Chinese, Indian, Egyptian and Greek civilizations emphasized the importance of sun exposure to promote health (1). Raab and von Tappeiner working in Munich made the discovery that an administered substance could cause photosensitivity and be used for the treatment of skin cancer. It was shown that a photosensitizer, light and molecular oxygen were required for a therapeutic response. They suggested tumors could be treated and preliminary results were reported. Dougherty later reported preferential accumulation of the photosensitizer in malignant tissue. More recently work has focused on optimization of the therapy and comparison of performance with established techniques.
Photodynamic Therapy
The basis of photodynamic therapy lies in the destruction of tissue due to the interaction of light with a photosensitizer in the presence of oxygen. The photosensitizer can either be administered or generated within the tissue. The light excites the ground state photosensitizer to an excited singlet state. This state is short lived and can decay to ground state directly emitting fluorescence, which can be used for photodiagnosis. However if the excited singlet state undergoes spin inversion to a metastable triplet state, which then transfers its energy to ground state oxygen, producing singlet oxygen and returning the photosensitizer to ground state. Singlet oxygen is highly reactive and cannot diffuse far before reacting with other molecules; such as cell membranes thus the cells are destroyed. It has been demonstrated that most of the damage occurs to the membranes around the mitochondria and lysosomes. Destructive proteins are released causing further cellular destruction leading to necrosis or apoptosis.
Cells have developed mechanisms to survive oxidative damage therefore a critical level of singlet oxygen must be produced. The singlet oxygen can also destroy the photosensitizer, which is called photodegradation.
Methods
Photosensitizers for Skin PDT
The accepted approach to photodynamic therapy is to administer a photosensitizer by application to an area of abnormality. Accumulation and retention of the photosensitizer is then allowed before illumination of the area with a measured amount of light. Much early PDT used photosensitizers that were crude porphyrin preparations. Later work used a more refined preparation, hematoporphyrin derivative (HpD), which is now yet further purified and marketed as Photofrin. A disadvantage of this photosensitizer is the prolonged generalized skin-photosensitivity that can last for up to 8 weeks, during which patients are advised to avoid sunlight.
Targeting of the photosensitizer to the tumor and preventing systemic photosensitization can be overcome with the application or administration of a photosensitizer pre-cursor that generates an endogenous photosensitizer. The tumor cells are expected to have a higher metabolic activity and hence more photosensitizer is accumulated in these cells compared to the surrounding tissue. The photosensitizer generally stays within the cell in which it was generated. The haem synthesis pathway is exploited in this way to generate the photosensitizer protoporphyrin IX (PpIX). Administration of 5-Aminolaevulinic acid (5-ALA) bypasses the negative feedback control, therefore relatively high concentrations of PpIX can temporarily be induced. The benefits of ALA are that of local topical application and that the photosensitivity is diminished after 24 hours. For skin PDT the 5-ALA is often applied topically in a carrier cream to the affected area. The development of ALA esters such as methyl aminolevulinate (m-ALA, Metvix™) has been demonstrated to be effective. One of the attractive features of topical ALA-PDT is that the treatment procedure is very simple and can be performed under outpatient conditions. Although generally well tolerated there is some discomfort involved during light exposure, which may persist for up to 24 hours. This has been described as a tingling or hot sensation, and in a fraction of cases requires the use of painkillers. The immediate response to therapy is usually a swelling and reddening of the site followed, after a period of days, by crusting of the lesion, with healing over a period of several weeks.
Early detection and delineation of the tumor borders, or of dysplastic precursors, is often difficult using the naked eye. Photodiagnosis, using a low concentration of photosensitizer, has emerged as a promising method for the early diagnosis of superficial non-melanoma skin cancers or areas of dysplasia (2).
Light Sources for Skin PDT
PpIX has a broad absorption spectrum centered at 405 nm, with a number of absorption maxima. Often a red light is used to provide deeper penetration into the tissue. A laser, in which case the light consists of a single wavelength, for example 635 nm, delivered via a thin optical fiber with a lens arrangement at the output, may generate the therapeutic light (3). This allows a defined area of uniform intensity to be incident upon the skin. However lasers are associated with considerable purchase and maintenance costs, which may limit the number of centers providing photodynamic therapy. Advances in semiconductor technology have allowed the development of diode laser sources that are significantly smaller and cheaper than the large and complex systems previously employed. A number of commercial devices, specifically designed for PDT, are now available. Alternatively, a non-laser source may be utilized (4-5). Although the output of this latter type of unit consists of a wider spectral band this does not appear to have any clinical significance. Importantly this lamp-based technology is much less expensive than a diode laser. Recently, it has become possible to manufacture clusters of high-intensity light-emitting diodes, emitting narrow bandwidth red light, as efficient non-coherent sources for PDT on the skin.
It is important to consider both the total light dose and the irradiance, (optical power divided by illuminated area), which defines the rate at which the light dose is delivered. There is an upper limit to the level of irradiance that can be applied before undesirable heating takes place; therefore treatment times of approximately 20 minutes for a typical total light dose of 150 J/cm 2 are common.
A number of attempts have been made to optimize the treatment. It has been suggested that fractionation of the light dose may be advantageous or reduced levels of irradiance so oxygen is consumed at a lower rate. Green light has been shown to be beneficial in reducing pain, with equal treatment efficacy, compared to red light for the treatment of actinic keratoses (6). However in the treatment of SCC in situ red light has demonstrated far higher clearance rates than green light, which is thought to be due to insufficient penetration of the green light, so deep dysplastic cells are not targeted (7) . A proprietary blue fluorescent light source has been developed, along with an ALA preparation called Levulan ® , specifically for the treatment of actinic keratoses of the face and scalp.
Applications of Skin PDT
Primary skin cancer is the second most common type of cancer in the UK (after the lung) with the three predominant forms originating from different types of cells found within the outer (epidermal) skin layer -resulting in basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma. It should be noted that PDT is not considered to be a treatment option for malignant melanoma, principally because these lesions are highly pigmented, and therefore would probably not allow sufficient light penetration.
Skin tumors were the first to be treated by photodynamic therapy due to their accessibility and prevalence. PDT has been widely reported for the treatment of many skin conditions including actinic keratoses (AK), squamous cell carcinoma in situ (Bowen's disease -SCC in situ), BCC and localized patch-stage cutaneous T-cell lymphoma (8-10). The treatment is restricted to superficial lesions due to the limited penetration of the light. Excellent cosmetic results are reported; with PDT being especially useful for multiple lesions and regions where the cosmetic results is of special importance.
Comparison of PDT with other therapies for non-melanoma skin cancer and pre-cursor lesions has been made (11). Superficial malignancies and pre-cancers can be treated by a number of routine methods, including surgical excision, curettage, radiotherapy cryotherapy and topical chemotherapy.
Actinic Keratoses: Early sun-induced changes in the skin may be classified as AK that generally consist of scaly discolored patches, most often found on the face and scalp of fair skinned adults. If not treated they can develop into cancers; approximately 40% of SCC's develop from AK's.
Several studies show clearance rates of 80-100% using ALA PDT for the treatment of actinic keratoses, with follow-up of 3-36 months (12-13). A randomized study comparing ALA PDT with topical application of 5-fluorouracil involved 17 patients with extensive disease on both hands. A reduction in the lesion area was demonstrated in 73% of the PDT patients, after single treatment, compared to 70% of the patients treated with 5-fluorouracil twice daily for three weeks (14). The response of non-hyperkeratotic facial actinic keratoses is known to be better than that of thick lesions (15-17).
A randomized multi-center study compared m-ALA PDT with cryotherapy for the treatment of 699 actinic keratoses. At 3 months follow-up, after a single treatment session, a 69% response rate was seen in the PDT group compared to 75% for cryotherapy, with improved cosmetic results for the PDT (18). A second study, using two PDT treatments at an interval of a week, demonstrated a 91% response rate for the m-ALA PDT compared to 68% for cryotherapy at 3 months, for 855 actinic keratoses (19) .
Phase III trials of Levulan (5-ALA, DUSA Pharm, Wilmington, MA) showed 72% complete response of non-hyperkeratotic lesions of the head, at 12 weeks, compared to 20% treated with light alone (20) .
Basal Cell Carcinomas:
The gold standard for the treatment of BCC is surgery. In particular, Mohs' surgery which involves the removal of the lesion layer by layer, with each section subject to pathological investigation, is optimal. Only when the point is reached at which the samples show no evidence of cancer is the surgery completed. This results in a long-term success rate (measured after 5 years) of approximately 99%. Although effective, this is a highly specialized, time-consuming and expensive procedure. Its availability is usually restricted to problematic cases and conventional excision surgery remains the most common therapy for BCC.
79-100% clearance rates have been reported for PDT to superficial BCC's (7, 13, 21) . Although reduced rates of 10-50% (22) are reported for nodular BCC, the use of debulking and penetration enhancers have achieved rates of 92 and 90% respectively (23).
A randomized study comparing ALA-PDT with cryotherapy, consisting of a dual freeze-thaw cycle, for superficial and nodular BCC, in 88 patients, demonstrated no significant difference in efficacy. However PDT showed better cosmetic results with fewer adverse events and faster healing. Recurrence rates were 25% for ALA PDT and 15% for cryotherapy. (24) A comparative study of m-ALA and cryotherapy for superficial BCC demonstrated clearance rates of 97% and 95% respectively at 3 months following one or two treatments.
Long-term follow-up data for ALA PDT is limited. 9% recurrence after an average of 45 months (16-73 months) for superficial BCC (25). 11% recurrence after an average of 35 months has been reported for superficial and nodular BCC following m-ALA PDT (26).
Association between BCC lesion diameter and response has been noted, (27) (28) although it is thought that tumor thickness remains the primary marker of response (29). Therefore new techniques of ALA delivery are have been attempted; adding a skin-permeable solvent to the ALA ointment is one approach; another is non-systemic (i.e. localized) injection of ALA solution. Situ (Bowen's) : 75-100% clearance rates have been reported for SCC in situ using ALA PDT, with follow-up periods of 2-36 months (7, 13) .
Squamous Cell Carcinoma In
A randomized study comparing ALA-PDT with cryotherapy for SCC in situ (Bowen's) showed that PDT was at least as effective as cryotherapy. A filtered xenon lamp delivered 125 J/cm 2 at a rate of 70 mW/cm 2 and was compared to a single freeze-thaw cycle of cryotherapy. Clearance was achieved in 75% of the PDT and 50% of the cryotherapy cases respectively after a single treatment (30). Fewer adverse events occurred for the PDT patients with less pain than for the cryotherapy treatments.
A randomized study comparing ALA-PDT (one to two visits) with 5% 5-fluorouracil (for 4 weeks) for SCC in situ, demonstrated clearance for 88% of the PDT and 67% of the 5-fluorouracil patients. At 12 months follow-up the clearance rates were 82% for the PDT group and 48% for the 5-fluorouracil groups (31). Clearance was demonstrated in the treatment of 88% larger patches of Bowen's, (at least 20 mm diameter) after one to three treatments. After 12 months 10% recurrence occurred reducing clearance levels to 78% (28). Site has not been demonstrated to have an effect on clearance rate.
Alternative therapies for the management of SCC in situ include direct excision, curettage, and radiotherapy however there is no comparative data for these therapies compared to ALA PDT.
Topical PDT has been demonstrated to be better than cryotherapy and equivalent to 5-fluorouracil in clearing non-hyperkeratotic actinic keratoses, with improved cosmetic effect. PDT has also been demonstrated to be beneficial for superficial BCC and for debulked nodular BCC, especially for large or multiple lesions, although guidelines suggest excision or cryotherapy as the treatments of choice (32). Topical PDT has been shown to be better than 5-fluorouracil and equivalent to cryotherapy for squamous cell carcinoma in situ (SCC in situ also known as Bowen's disease). PDT may be particularly suitable for large and multiple lesions with few adverse events and good cosmetic effect (28, 33) .
Primary Cutaneous T-cell Lymphoma:
Cutaneous T-cell lymphoma (CTCL) refers to a collection of cancers that are derived from the lymphatic system, which involve T-cells (so named as they are matured in the Thymus gland). Tcells are major components of the immune system, the function of which is to protect the body from disease. Those T-cells affected in CTCL have an affinity for the skin, so that most patients develop symptoms on the skin before there is any evidence of disease elsewhere. The malignant T-cells can accumulate on the skin in patches, and if left untreated (or misdiagnosed as psoriasis or Figure 4 : 12 weeks after a single treatment with 5-ALA photodynamic therapy the disease has been eradicated with minimal scarring. eczema) may develop as tumors. The risk of spreading to other sites increases as more of the skin surface becomes involved. There is limited evidence supporting the use of topical PDT in the treatment of primary CTCL (34).
Benign Skin Disease: Stimulated by the success achieved with superficial cancers, a number of non-malignant conditions are currently under clinical investigation. These include psoriasis, acne, viral warts and hair removal. Results using topical ALA for psoriasis have been variable, and the discomfort of therapy might preclude this as a practical option. By contrast a rare skin condition called epidermodysplasia verrruciformis, caused by human papilloma viruses, shows a favorable response. A report from Japan has demonstrated positive results from a single treatment in a group of acne patients that was maintained for at least 6 months.
Protocol:
The area to be treated is prepared with the use of Vaseline™ to soften the skin for a week before the treatment. The area is debrided to remove any crust to enhance the penetration of the photosensitizing drug. The diameter of the lesion is measured and a one-centimeter disease free margin is treated. 5-aminolaevulinic acid oil in water emulsion 0.2g/ml in Unguentum Merck is applied at a rate of 10 mg/cm 2 . The area is covered with a Tegaderm dressing to keep the cream in place and an occlusive dressing. The patient returns four hours later to expose the lesion to the light. Lidocaine is injected into the area to relieve any burning sensation and pain that may occur. In Gloucester, the area is exposed to red laser light at 630 nm, generated by a Nd:YAG/KTP pumped liquid dye laser. A surface illuminating fiber optic device provides uniform field illumination. A total dose of 150 J/cm 2 is delivered at a maximum dose rate of 150 mW/cm 2 .
All patients were seen to have clearance of the lesion and good cosmetic results following a single treatment session. Two examples of the therapeutic results are presented here. Figures 1 and 2 illustrate the excellent results achieved for the treatment of an extensive area of basal cell carcinoma. Figures 3 and 4 show a region of Bowen's disease before and after 5-ALA photodynamic therapy (35).
24 patients were treated with ALA PDT. 6 patients showed some recurrence after 7 to 26 months follow up. 3 of the recurrent areas were noted as being thick before treatment, therefore it may be questionable whether the treatment penetrated deeply enough. One area that recurred was one of the first areas to be treated in this study. Following recurrence in this patient the protocol was amended to add a one-centimeter disease free margin to the treatment area. Many of the patients in this study were referred for PDT after more conventional treatments had failed. Two of the recurrent areas had previously been treated with cryotherapy on 8 to 12 occasions with recurrence every 3 months.
Conclusions
Good to excellent cosmetic results are widely reported, although some localized hair loss and temporary pigment change and erythemal color has been noted. PDT is a noninvasive therapy and provides advantages for multiple or large areas of AK, Bowen's disease, BCC, CTCL and possibly for psoriasis, acne and viral warts. Topical ALA use avoids systemic photosensitization and the cosmetic results are generally very good. It has been shown that generalized treatment protocols may not achieve the best results for all skin conditions. A single treatment of ALA-PDT may be appropriate for Bowen's and AK's, but a repeat treatment protocol would be more advantageous for superficial BCC's or for larger lesions. Longer term follow-up and further comparison data from multi-center studies is required.
Research is required to further optimize PDT protocols and develop new photosensitizers. The ability of PDT to play its part in dermatological practice has been demonstrated.
